SCHEMBL6433565

SCHEMBL6433565

CC(C)(C)OC(=O)N(CCO)CCC(=O)N1CC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 20/20 0.61
FLT3 P36888 2/20 0.61
KIT P10721 1/20 0.61
EGFR P00533 5/20 0.58
LCK P06239 2/20 0.54
ITK Q08881 2/20 0.54
TEC P42680 2/20 0.54
TXK P42681 2/20 0.54
BMX P51813 2/20 0.54
RIPK2 O43353 1/20 0.54
NR1I2 O75469 1/20 0.54
SLC22A3 O75751 1/20 0.54
LATS1 O95835 1/20 0.54
NUDT14 O95848 1/20 0.54
ABL1 P00519 1/20 0.54
ERBB2 P04626 1/20 0.54
FYN P06241 1/20 0.54
PGR P06401 1/20 0.54
CSF1R P07333 1/20 0.54
YES1 P07947 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5803241 0.93 BTK (0.61) BTKFLT3KITEGFRLCK
SCHEMBL7138343 0.91 BTK (0.64) BTKFLT3KITEGFRLCK
SCHEMBL6465778 0.88 BTK (0.56) BTKFLT3KITEGFRLCK
SCHEMBL6430256 0.86 BTK (0.69) BTKFLT3KITEGFRLCK
SCHEMBL5802149 0.84 BTK (0.66) BTKFLT3KITEGFRLCK
SCHEMBL29671211 0.83 BTK (0.70) BTKFLT3KITEGFRLCK
SCHEMBL5801638 0.83 BTK (0.70) BTKFLT3KITEGFRLCK
SCHEMBL6645874 0.83 BTK (0.85) BTKFLT3KITEGFRLCK
SCHEMBL5822934 0.82 BTK (0.48) BTKFLT3KITEGFRLCK
SCHEMBL5816014 0.81 BTK (0.66) BTKFLT3KITEGFRLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6921763-B2 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2005-07-26 US disclosed
US-6660744-B1 Kinase inhibitors ABBOTT GMBH & CO. KG (DE) 2003-12-09 US disclosed
EP-1212327-B1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS BASF AG (DE) 2003-08-20 EP disclosed
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2002-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents DPYD, CYP2D6, UGT1A1 BTK 1020/4885FLT3 67/4885KIT 445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.